Immunotherapy-induced uveitis involved anti-PD-1 agents (pembrolizumab (23 cases, 24.7%) and nivolumab (13 cases, 14.0%)) and T-lymphocyte antigen-4 (ipilimumab (18 cases, 19.4%) plus ipilimumab and nivolumab (6 cases, 6.5%)). Here, PDCD1 is linked to uveitis.